Telephone: 33 4 72 68 19 70; FAX: 33 4 72 68 19 71
Management of patients with decompensated hepatitis B virus associated cirrhosis
Article first published online: 29 SEP 2008
Copyright © 2008 American Association for the Study of Liver Diseases
Supplement: Liver Transplant for Viral Hepatitis and Fulminant Hepatic Failure
Volume 14, Issue Supplement S2, pages S1–S7, October 2008
How to Cite
Zoulim, F., Radenne, S. and Ducerf, C. (2008), Management of patients with decompensated hepatitis B virus associated cirrhosis. Liver Transpl, 14: S1–S7. doi: 10.1002/lt.21615
- Issue published online: 29 SEP 2008
- Article first published online: 29 SEP 2008
- Manuscript Accepted: 21 JUL 2008
- Manuscript Received: 13 MAY 2008
- 1Hepatitis B virus replication is associated with a severe outcome in patients with decompensated cirrhosis.
- 2Viral suppression induced by antivirals results in a clinical improvement that allows liver transplantation to be delayed or avoided.
- 3Early treatment intervention is mandatory in patients with decompensated cirrhosis because of the delay in the restoration of liver functions.
- 4Lamivudine is no longer the drug of choice because the initial enthusiasm has been tempered by the high rate of resistance development.
- 5Early add-on therapy with adefovir allows us to rescue lamivudine resistance, but its use may be limited by nephrotoxicity.
- 6Studies are ongoing with the newer generation of antivirals (telbivudine, tenofovir, entecavir, and emtricitabine) in monotherapy or in combination to determine the best strategy for achieving rapid and prolonged suppression of viral replication. These improved strategies should enhance treatment success enough to obtain clinical stabilization, to delay or prevent the need for transplantation, and to reduce the risk of hepatitis B virus recurrence on the graft.
Liver Transpl 14:S1–S7, 2008. © 2008 AASLD.